First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context

Despite the availability of multiple therapeutic options and strategies, patients with type 2 diabetes mellitus (T2DM) the world over have inadequate glycaemic control and India is no exception. Patients with T2DM in India have benefitted from glucagon-like peptide-1 analogues similar to that of pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajput, Rajesh, Ghosh, Sujoy, Banerjee, Samar, Bansal, Beena, Chawla, Manoj, Ahluwalia, Abhay I., Lathia, Tejal, Das, Ashok K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815186/
https://www.ncbi.nlm.nih.gov/pubmed/36618518
http://dx.doi.org/10.4103/ijem.ijem_217_22
_version_ 1784864300216614912
author Rajput, Rajesh
Ghosh, Sujoy
Banerjee, Samar
Bansal, Beena
Chawla, Manoj
Ahluwalia, Abhay I.
Lathia, Tejal
Das, Ashok K.
author_facet Rajput, Rajesh
Ghosh, Sujoy
Banerjee, Samar
Bansal, Beena
Chawla, Manoj
Ahluwalia, Abhay I.
Lathia, Tejal
Das, Ashok K.
author_sort Rajput, Rajesh
collection PubMed
description Despite the availability of multiple therapeutic options and strategies, patients with type 2 diabetes mellitus (T2DM) the world over have inadequate glycaemic control and India is no exception. Patients with T2DM in India have benefitted from glucagon-like peptide-1 analogues similar to that of patients from other parts of the world. However, subcutaneous treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is limited by their injectable mode of administration. The present review highlights barriers to incretinisation with GLP-1RAs and the role of first-in-class oral semaglutide in the Indian context and provides guidance to physicians on its initiation and uses.
format Online
Article
Text
id pubmed-9815186
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-98151862023-01-06 First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context Rajput, Rajesh Ghosh, Sujoy Banerjee, Samar Bansal, Beena Chawla, Manoj Ahluwalia, Abhay I. Lathia, Tejal Das, Ashok K. Indian J Endocrinol Metab Review Article Despite the availability of multiple therapeutic options and strategies, patients with type 2 diabetes mellitus (T2DM) the world over have inadequate glycaemic control and India is no exception. Patients with T2DM in India have benefitted from glucagon-like peptide-1 analogues similar to that of patients from other parts of the world. However, subcutaneous treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is limited by their injectable mode of administration. The present review highlights barriers to incretinisation with GLP-1RAs and the role of first-in-class oral semaglutide in the Indian context and provides guidance to physicians on its initiation and uses. Wolters Kluwer - Medknow 2022 2022-11-22 /pmc/articles/PMC9815186/ /pubmed/36618518 http://dx.doi.org/10.4103/ijem.ijem_217_22 Text en Copyright: © 2022 Indian Journal of Endocrinology and Metabolism https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Rajput, Rajesh
Ghosh, Sujoy
Banerjee, Samar
Bansal, Beena
Chawla, Manoj
Ahluwalia, Abhay I.
Lathia, Tejal
Das, Ashok K.
First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context
title First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context
title_full First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context
title_fullStr First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context
title_full_unstemmed First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context
title_short First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context
title_sort first-in-class oral semaglutide: overcoming barriers of incretinisation in the indian context
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815186/
https://www.ncbi.nlm.nih.gov/pubmed/36618518
http://dx.doi.org/10.4103/ijem.ijem_217_22
work_keys_str_mv AT rajputrajesh firstinclassoralsemaglutideovercomingbarriersofincretinisationintheindiancontext
AT ghoshsujoy firstinclassoralsemaglutideovercomingbarriersofincretinisationintheindiancontext
AT banerjeesamar firstinclassoralsemaglutideovercomingbarriersofincretinisationintheindiancontext
AT bansalbeena firstinclassoralsemaglutideovercomingbarriersofincretinisationintheindiancontext
AT chawlamanoj firstinclassoralsemaglutideovercomingbarriersofincretinisationintheindiancontext
AT ahluwaliaabhayi firstinclassoralsemaglutideovercomingbarriersofincretinisationintheindiancontext
AT lathiatejal firstinclassoralsemaglutideovercomingbarriersofincretinisationintheindiancontext
AT dasashokk firstinclassoralsemaglutideovercomingbarriersofincretinisationintheindiancontext

Ejemplares similares